Caredx Inc

CDNANASDAQ · USD
77.88USD0.00 (-2.42%)
5810

Caredx Inc (CDNA) Covered Calls

Caredx Inc trades in the Diagnostics & Research industry with an IV Rank of 21.83%, low versus the past year. CDNA's highest covered call setup is the $100.00 strike expiring Nov 20, 2026, sorted by theoretical annualized return. It's 28.40% out of the money with 7 days to expiration, a 28.47% return until expiration, and a 1,484.34% theoretical annualized return. Across the setups shown, annualized returns run from 123.19% to 1,484.34% at strikes between $80.00 and $125.00, with 7 to 126 days to expiration, as of Nov 13, 2026.

Read more

Running CDNA covered calls helps you generate income from Caredx Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best CDNA covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If CDNA stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling CDNA covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given CDNA covered call is worth writing.

CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software.

2026-11-207100.0028.400.052.102217.0028.471484.34-0.06+0.14102.05
2026-11-20785.009.140.601.95772.009.91516.88-0.77+0.25611.35
2026-12-183595.0021.980.701.701782.0022.88238.62-0.90+0.175741.00
2026-11-20780.002.721.254.00337.004.33225.63-1.61+0.435142.75
2026-12-183590.0015.561.102.751322.0016.97177.02-1.41+0.25251.65
2027-03-19126125.0060.500.104.904722.0060.63175.64-0.13+0.1804.80
2027-03-19126120.0054.080.204.904232.0054.34157.41-0.26+0.1804.70
2027-03-19126115.0047.660.104.903722.0047.79138.44-0.13+0.1914.80
2027-02-1998105.0034.821.104.302822.0036.24134.96-1.41+0.221153.20
2027-03-19126110.0041.241.004.803312.0042.53123.19-1.28+0.2203.80

As of Nov 13, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →

Stock Statistics

  • IndustryDiagnostics & Research
  • SectorHealthcare
  • IV Rank21.83% Low
  • Market cap (M$)4,092
  • 52 weeks high-14.30%
  • 52 weeks low414.06%
  • Analyst recommendationStrong Buy
    1.50
  • Target price$94.43
    21.25% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-10-29
  • P/E32.53
  • Future P/E49.79
  • EPS (ttm)2.39
  • EPS growth next 5 years55.36%

As of Nov 13, 2026